Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNK13 | Q9HB14 | 14/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | HTT | P42858 | 2/20 | 0.47 |
| ▸ | TP53 | P04637 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.45 |
| ▸ | RPS6KA5 | O75582 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29995472 | 1.00 | KCNK13 (1.00) | KCNK13ALDH1A1TSHRHTTTP53 | |
| SCHEMBL29995154 | 0.86 | KCNK13 (1.00) | KCNK13ALDH1A1TSHRHTTTP53 | |
| SCHEMBL26922690 | 0.86 | KCNK13 (1.00) | KCNK13ALDH1A1TSHRHTTTP53 | |
| SCHEMBL29995758 | 0.85 | KCNK13 (1.00) | KCNK13ALDH1A1TSHRHTTTP53 | |
| SCHEMBL26922920 | 0.85 | KCNK13 (1.00) | KCNK13ALDH1A1TSHRHTTTP53 | |
| SCHEMBL26921287 | 0.84 | KCNK13 (0.74) | KCNK13ALDH1A1TSHRHTTTP53 | |
| SCHEMBL29995770 | 0.84 | KCNK13 (0.74) | KCNK13ALDH1A1TSHRHTTTP53 | |
| SCHEMBL26921718 | 0.83 | KCNK13 (0.72) | KCNK13ALDH1A1TSHRHTTTP53 | |
| SCHEMBL29995802 | 0.83 | KCNK13 (0.72) | KCNK13ALDH1A1TSHRHTTTP53 | |
| SCHEMBL29995185 | 0.82 | KCNK13 (1.00) | KCNK13ALDH1A1TSHRHTTTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240158385-A1 | NOVEL COMPOUNDS | Cerevance, Inc. | 2024-05-16 | — | — | US | claimed |
| EP-4288433-A1 | NOVEL COMPOUNDS | Cerevance, Inc. (US) | 2023-12-13 | — | — | EP | claimed |
| US-20240158385-A1 | NOVEL COMPOUNDS | Cerevance, Inc. | 2024-05-16 | — | — | US | disclosed |
| EP-4288433-A1 | NOVEL COMPOUNDS | Cerevance, Inc. (US) | 2023-12-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240158385-A1 | NOVEL COMPOUNDS | KCNK3, KCNA4, KCNK13 | KCNK13 3/4885ALDH1A1 2143/4885TSHR 2243/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.